MX2023001538A - Composiciones y metodos para inhibir la expresion de lpa. - Google Patents
Composiciones y metodos para inhibir la expresion de lpa.Info
- Publication number
- MX2023001538A MX2023001538A MX2023001538A MX2023001538A MX2023001538A MX 2023001538 A MX2023001538 A MX 2023001538A MX 2023001538 A MX2023001538 A MX 2023001538A MX 2023001538 A MX2023001538 A MX 2023001538A MX 2023001538 A MX2023001538 A MX 2023001538A
- Authority
- MX
- Mexico
- Prior art keywords
- lpa
- expression
- compositions
- inhibiting
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/312—Phosphonates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3521—Methyl
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3525—MOE, methoxyethoxy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
- C12N2310/3533—Halogen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063061676P | 2020-08-05 | 2020-08-05 | |
| US202063074779P | 2020-09-04 | 2020-09-04 | |
| PCT/US2021/071109 WO2022032288A1 (en) | 2020-08-05 | 2021-08-05 | Compositions and methods for inhibiting lpa expression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023001538A true MX2023001538A (es) | 2023-03-08 |
Family
ID=77519885
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023001538A MX2023001538A (es) | 2020-08-05 | 2021-08-05 | Composiciones y metodos para inhibir la expresion de lpa. |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US12435336B2 (https=) |
| EP (1) | EP4192954A1 (https=) |
| JP (2) | JP7476422B2 (https=) |
| KR (2) | KR102812602B1 (https=) |
| CN (1) | CN116323943A (https=) |
| AU (2) | AU2021320550B2 (https=) |
| BR (1) | BR112023001957A2 (https=) |
| CA (1) | CA3185348A1 (https=) |
| IL (1) | IL300338A (https=) |
| MX (1) | MX2023001538A (https=) |
| TW (2) | TWI886314B (https=) |
| WO (1) | WO2022032288A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102812602B1 (ko) | 2020-08-05 | 2025-05-28 | 다이서나 파마수이티컬, 인크. | Lpa 발현을 저해하기 위한 조성물 및 방법 |
| IL312811A (en) | 2021-11-16 | 2024-07-01 | Shanghai Argo Biopharmaceutical Co Ltd | Composition and method for inhibiting angiotensinogen (agt) protein expression |
| WO2023109940A1 (zh) * | 2021-12-16 | 2023-06-22 | 上海拓界生物医药科技有限公司 | 靶向lpa的sirna及缀合物 |
| CN114703184B (zh) * | 2022-03-11 | 2024-06-18 | 厦门甘宝利生物医药有限公司 | Lpa抑制剂及其用途 |
| KR20250005108A (ko) * | 2022-04-15 | 2025-01-09 | 다이서나 파마수이티컬, 인크. | Scap 활성을 조절하기 위한 조성물 및 방법 |
| KR20250087521A (ko) * | 2022-08-11 | 2025-06-16 | 시리우스 테라퓨틱스, 인크. | Lp(a)의 발현을 억제하기 위한 다중핵산 분자, 약제학적 조성물 및 이의 용도 |
| CN115851723B (zh) * | 2022-10-24 | 2023-10-03 | 厦门甘宝利生物医药有限公司 | 一种抑制lpa基因表达的rna抑制剂及其应用 |
| AU2023384015A1 (en) | 2022-11-23 | 2025-05-22 | Eli Lilly And Company | Methods of synthesizing a targeting ligand-conjugated nucleotide phosphoramidite |
| CN120239704A (zh) | 2022-11-23 | 2025-07-01 | 伊莱利利公司 | 合成4'-磷酸盐类似物核苷酸亚磷酰胺的方法 |
| AU2023408776A1 (en) | 2022-12-22 | 2025-07-10 | Eli Lilly And Company | Oligonucleotide fragments and methods of making rnai agents using the same |
| IL321855A (en) | 2023-01-13 | 2025-08-01 | Lilly Co Eli | Pharmaceutical preparations containing therapeutic oligonucleotides and dosage regimens using the same |
| KR20250163949A (ko) * | 2023-03-20 | 2025-11-21 | 버브 테라퓨틱스, 인크. | 심혈관 질환의 치료를 위한 lpa 유전자의 생체내 닉카제-기반 편집 |
| CN118685405A (zh) * | 2023-06-20 | 2024-09-24 | 施能康医药科技(苏州)有限公司 | 靶向脂蛋白a的核酸及其用途 |
| WO2025064821A2 (en) | 2023-09-21 | 2025-03-27 | Ionis Pharmaceuticals, Inc. | Compounds and methods for inhibiting lpa |
| WO2025082058A1 (zh) * | 2023-10-16 | 2025-04-24 | 润佳(上海)医药技术有限公司 | 一种抑制LPA基因表达的dsRNA及其用途 |
| WO2025087442A1 (zh) * | 2023-10-27 | 2025-05-01 | 北京安龙生物医药有限公司 | 靶向脂蛋白a的寡核苷酸及其用途 |
| CN120020252A (zh) * | 2023-11-17 | 2025-05-20 | 纳肽得(青岛)生物医药有限公司 | 抑制LPA表达的siRNA及其用途 |
| WO2025117709A2 (en) * | 2023-11-29 | 2025-06-05 | Sanegene Bio Usa Inc. | Small interfering rna targeting lp(a) and uses thereof |
| CN120098993A (zh) * | 2023-12-05 | 2025-06-06 | 广东东阳光药业股份有限公司 | 一种新型的双链siRNA、其缀合物及其用途 |
| WO2025170868A1 (en) * | 2024-02-05 | 2025-08-14 | Sirius Therapeutics, Inc. | Polynucleic acid molecules for inhibiting expression of lp(a) or apoc3, pharmaceutical compositions, and uses thereof |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6469158B1 (en) | 1992-05-14 | 2002-10-22 | Ribozyme Pharmaceuticals, Incorporated | Synthesis, deprotection, analysis and purification of RNA and ribozymes |
| US5977343A (en) | 1992-05-14 | 1999-11-02 | Ribozyme Pharmaceuticals, Inc. | Synthesis, deprotection, analysis and purification of RNA and ribozymes |
| US5804683A (en) | 1992-05-14 | 1998-09-08 | Ribozyme Pharmaceuticals, Inc. | Deprotection of RNA with alkylamine |
| WO1995006731A2 (en) | 1993-09-02 | 1995-03-09 | Ribozyme Pharmaceuticals, Inc. | Non-nucleotide containing enzymatic nucleic acid |
| US5889136A (en) | 1995-06-09 | 1999-03-30 | The Regents Of The University Of Colorado | Orthoester protecting groups in RNA synthesis |
| US5998203A (en) | 1996-04-16 | 1999-12-07 | Ribozyme Pharmaceuticals, Inc. | Enzymatic nucleic acids containing 5'-and/or 3'-cap structures |
| US6111086A (en) | 1998-02-27 | 2000-08-29 | Scaringe; Stephen A. | Orthoester protecting groups |
| PT1309726E (pt) | 2000-03-30 | 2010-03-08 | Whitehead Biomedical Inst | Mediadores de interferência por rna específicos de sequência de rna |
| US20040259247A1 (en) | 2000-12-01 | 2004-12-23 | Thomas Tuschl | Rna interference mediating small rna molecules |
| US20050159378A1 (en) | 2001-05-18 | 2005-07-21 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA) |
| JP2005508196A (ja) | 2001-11-07 | 2005-03-31 | アプレラ コーポレイション | 核酸分析の汎用ヌクレオチド |
| US20070265220A1 (en) | 2004-03-15 | 2007-11-15 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
| WO2007030167A1 (en) | 2005-09-02 | 2007-03-15 | Nastech Pharmaceutical Company Inc. | Modification of double-stranded ribonucleic acid molecules |
| JP2012504389A (ja) | 2008-09-22 | 2012-02-23 | ダイセルナ ファーマシューティカルズ， インコーポレイテッド | 修飾を有するｄｓＲＮＡによる遺伝子発現の特異的な阻害のための組成物および方法 |
| US8691971B2 (en) | 2008-09-23 | 2014-04-08 | Scott G. Petersen | Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating RNA interference |
| AU2009336191B2 (en) | 2008-12-18 | 2017-08-24 | Novo Nordisk A/S | Extended dicer substrate agents and methods for the specific inhibition of gene expression |
| US20100249214A1 (en) | 2009-02-11 | 2010-09-30 | Dicerna Pharmaceuticals | Multiplex dicer substrate rna interference molecules having joining sequences |
| US8927513B2 (en) | 2009-07-07 | 2015-01-06 | Alnylam Pharmaceuticals, Inc. | 5′ phosphate mimics |
| WO2011133871A2 (en) | 2010-04-22 | 2011-10-27 | Alnylam Pharmaceuticals, Inc. | 5'-end derivatives |
| JP2015501155A (ja) | 2011-10-25 | 2015-01-15 | アイシス ファーマシューティカルズ， インコーポレーテッド | Ｇｃｃｒ発現のアンチセンス調整 |
| EP2928877B1 (en) | 2012-12-06 | 2020-01-22 | Merck Sharp & Dohme Corp. | Disulfide masked prodrug compositions and methods |
| JP2017522046A (ja) | 2014-06-06 | 2017-08-10 | ソルスティス バイオロジクス，リミティッド | 生物可逆的および生物不可逆的基を有するポリヌクレオチド構築物 |
| JP7105065B2 (ja) | 2014-12-15 | 2022-07-22 | ダイセルナ ファーマシューティカルズ， インコーポレイテッド | リガンド修飾二本鎖核酸 |
| JOP20160211B1 (ar) * | 2015-10-01 | 2021-08-17 | Arrowhead Pharmaceuticals Inc | تراكيب وأساليب لتثبيط تعبير جيني للـ lpa |
| KR102350647B1 (ko) | 2016-09-02 | 2022-01-14 | 다이서나 파마수이티컬, 인크. | 4'-포스페이트 유사체 및 이를 포함하는 올리고뉴클레오타이드 |
| MX2020004897A (es) | 2017-11-13 | 2020-10-05 | Silence Therapeutics Gmbh | Acidos nucleicos para inhibir la expresion de lpa en una celula. |
| AR113490A1 (es) * | 2017-12-12 | 2020-05-06 | Amgen Inc | CONSTRUCCIONES DE ARNi PARA INHIBIR LA EXPRESIÓN DE PNPLA3 Y MÉTODOS DE USO DE LAS MISMAS |
| US20230078200A1 (en) | 2019-12-09 | 2023-03-16 | Amgen Inc. | RNAi CONSTRUCTS AND METHODS FOR INHIBITING LPA EXPRESSION |
| KR102812602B1 (ko) | 2020-08-05 | 2025-05-28 | 다이서나 파마수이티컬, 인크. | Lpa 발현을 저해하기 위한 조성물 및 방법 |
-
2021
- 2021-08-05 KR KR1020237006019A patent/KR102812602B1/ko active Active
- 2021-08-05 CN CN202180058046.7A patent/CN116323943A/zh active Pending
- 2021-08-05 TW TW110128888A patent/TWI886314B/zh active
- 2021-08-05 AU AU2021320550A patent/AU2021320550B2/en active Active
- 2021-08-05 CA CA3185348A patent/CA3185348A1/en active Pending
- 2021-08-05 JP JP2023507767A patent/JP7476422B2/ja active Active
- 2021-08-05 TW TW114118397A patent/TW202535432A/zh unknown
- 2021-08-05 EP EP21762318.0A patent/EP4192954A1/en active Pending
- 2021-08-05 US US18/040,302 patent/US12435336B2/en active Active
- 2021-08-05 BR BR112023001957A patent/BR112023001957A2/pt unknown
- 2021-08-05 IL IL300338A patent/IL300338A/en unknown
- 2021-08-05 MX MX2023001538A patent/MX2023001538A/es unknown
- 2021-08-05 KR KR1020257016689A patent/KR20250077604A/ko active Pending
- 2021-08-05 WO PCT/US2021/071109 patent/WO2022032288A1/en not_active Ceased
-
2024
- 2024-03-07 JP JP2024034617A patent/JP7805386B2/ja active Active
- 2024-08-16 US US18/807,591 patent/US12252691B2/en active Active
-
2025
- 2025-08-04 US US19/290,213 patent/US20260071219A1/en active Pending
- 2025-10-17 AU AU2025252633A patent/AU2025252633A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US12435336B2 (en) | 2025-10-07 |
| BR112023001957A2 (pt) | 2023-04-25 |
| IL300338A (en) | 2023-04-01 |
| AU2021320550B2 (en) | 2025-11-06 |
| KR20250077604A (ko) | 2025-05-30 |
| JP2024081668A (ja) | 2024-06-18 |
| US12252691B2 (en) | 2025-03-18 |
| KR102812602B1 (ko) | 2025-05-28 |
| US20260071219A1 (en) | 2026-03-12 |
| EP4192954A1 (en) | 2023-06-14 |
| AU2021320550A1 (en) | 2023-02-16 |
| JP7476422B2 (ja) | 2024-04-30 |
| TW202535432A (zh) | 2025-09-16 |
| JP7805386B2 (ja) | 2026-01-23 |
| JP2023536974A (ja) | 2023-08-30 |
| US20240344063A1 (en) | 2024-10-17 |
| WO2022032288A1 (en) | 2022-02-10 |
| CN116323943A (zh) | 2023-06-23 |
| AU2025252633A1 (en) | 2025-11-27 |
| TWI886314B (zh) | 2025-06-11 |
| CA3185348A1 (en) | 2022-02-10 |
| US20240401053A1 (en) | 2024-12-05 |
| TW202220673A (zh) | 2022-06-01 |
| KR20230043912A (ko) | 2023-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023001538A (es) | Composiciones y metodos para inhibir la expresion de lpa. | |
| CL2020002146A1 (es) | Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer. | |
| CL2021002326A1 (es) | Composiciones de arni contra el angiotensinógeno (agt) y métodos para su uso (divisional de solicitud n° 202002865) | |
| MX2023001450A (es) | Composiciones y metodos para la inhibicion de la expresion de plp1. | |
| MX2020010368A (es) | Compuestos dirigidos a brm y métodos de uso asociados. | |
| MX2022011550A (es) | Composiciones y métodos para inhibir la expresión de angptl3. | |
| BR112022023025A2 (pt) | Moduladores de htt para tratar doença de huntington | |
| MX2021015262A (es) | Inhibidores de prmt5. | |
| MX2022000453A (es) | Compuestos útiles para tratar infecciones por virus de influenza. | |
| CL2021002878A1 (es) | Tratamiento y prevención de enfermedades metabólicas | |
| BR112021022758A2 (pt) | Compostos de 1-oxo-isoindolina-5-carboxamida substituídos, suas composições e métodos de tratamento com os mesmos | |
| MX2020010999A (es) | Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos. | |
| MX379543B (es) | Purinonas como inhibidores de proteasa específica de ubiquitina 1. | |
| BR112018074185A2 (pt) | 3-oxo-2,6-difenil-2,3-di-hidropiridazina-4-carboxamidas | |
| AR107579A1 (es) | Composiciones y métodos para disminuir la expresión de tau | |
| PE20190626A1 (es) | Composiciones y metodos para modular la expresion del factor b del complemento | |
| BR112015022462A8 (pt) | inibidores de ido, composição farmacêutica, método de inibição de atividade de indolamina 2,3-dioxigenase e uso dos referidos inibidores | |
| NI202000085A (es) | Moduladores de la expresión de apol1 | |
| MX2023012048A (es) | Composiciones y metodos para inhibir cetohexoquinasa (khk). | |
| BR112022005627A2 (pt) | Composto de fórmula estrutural i ou um sal do mesmo, composição farmacêutica e uso de um composto | |
| CL2021001903A1 (es) | Tratamiento de la hepatotoxicidad | |
| SA522441554B1 (ar) | Ripk1 مركبات أيزوكسازوليدين كمثبطات واستخدامها | |
| JOP20230301A1 (ar) | تركيبات وطرق لتثبيط التعبير الوراثي عن مكون اختزال أميدوكسيم المتقدري 1 (marc1) | |
| MX2023012216A (es) | Composiciones y metodos para modular la expresion de pnpla3. | |
| CO2024017422A2 (es) | Composiciones y métodos para inhibir la expresión de serina proteasa transmembrana 6 (tmprss6) |